73 filings
Page 2 of 4
6-K
7rhchysl1b
9 Mar 23
Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022
4:00pm
6-K
7l994an3o5zfa4rlh
17 Jan 23
Current report (foreign)
7:00am
6-K
aeo0cr
10 Nov 22
Molecular Partners Presents Positive Interim Safety and Mechanistic Data From Ongoing Phase 1 Trial of MP0317 for Treatment of Solid Tumors
8:00am
6-K
n58xdpsgikq
27 Oct 22
Current report (foreign)
4:01pm
6-K
j71t4 xquu44qtac
27 Oct 22
Current report (foreign)
4:00pm
6-K/A
t5gcq
31 Aug 22
Current report (foreign) (amended)
12:28pm
6-K
u7esws 8eio0
25 Aug 22
Molecular Partners Reports Corporate Highlights and H1 2022 Financials
4:31pm
EFFECT
glroq
13 Jul 22
Notice of effectiveness
12:15am
F-3
subnvhrytyj13cvpp8z
1 Jul 22
Shelf registration (foreign)
9:10am
6-K
wx5fqqae4n0w
13 Jun 22
Current report (foreign)
6:10am
6-K
hlfrbq7wwu 15hwytb
12 May 22
Current report (foreign)
4:05pm
6-K
wle 4j2umln
26 Apr 22
Molecular Partners to Regain Global Rights for MP0310 from Amgen
4:05pm
6-K
wuwpklznzmysup2
26 Apr 22
Molecular Partners Provides Update on Ensovibep Following Novartis Quarterly Earnings Call
2:05pm
6-K
hokpb 9jv
14 Apr 22
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
6:05am
6-K
uy2n9q g3
17 Mar 22
Molecular Partners Publishes Invitation to Annual General Meeting 2022
6:10am
6-K
0gm7tfo ueo
15 Mar 22
Molecular Partners Reports Corporate Highlights From Q4 2021 and Key Financials for Full Year 2021
4:30pm
20-F
ioz2 9pa6ojxwqu4b
15 Mar 22
Annual report (foreign)
4:25pm
6-K
78qq0x r2b
10 Feb 22
Emergency Use Authorization Request for Ensovibep Submitted to the US Food and Drug Administration for the Treatment of COVID-19
6:10am
6-K
mq8xvshn
18 Jan 22
Molecular Partners Finalizes License Agreement with Novartis for Ensovibep for COVID-19
6:10am
6-K
6vhg lyshgk0
10 Jan 22
Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19
9:18am